Biogen’s recently reported positive Phase 2 trial results for BAN2401 rekindle hopes for the amyloid hypothesis and also more widespread use of amyloid imaging radiopharmaceuticals.
Has Amyloid-Based Research Turned The Corner?
Biogen’s recently reported positive Phase 2 trial results for BAN2401 rekindle hopes for the amyloid hypothesis and also more widespread use of amyloid imaging radiopharmaceuticals.